ATE497492T1 - Reinigung von montelukast - Google Patents

Reinigung von montelukast

Info

Publication number
ATE497492T1
ATE497492T1 AT06786369T AT06786369T ATE497492T1 AT E497492 T1 ATE497492 T1 AT E497492T1 AT 06786369 T AT06786369 T AT 06786369T AT 06786369 T AT06786369 T AT 06786369T AT E497492 T1 ATE497492 T1 AT E497492T1
Authority
AT
Austria
Prior art keywords
montelukast
cleaning
impurity
isolation
provides methods
Prior art date
Application number
AT06786369T
Other languages
English (en)
Inventor
Greta Sterimbaum
Evgeny Shapiro
Kobi Chen
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE497492T1 publication Critical patent/ATE497492T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Quinoline Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06786369T 2005-07-05 2006-07-05 Reinigung von montelukast ATE497492T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69700005P 2005-07-05 2005-07-05
PCT/US2006/026192 WO2007005965A1 (en) 2005-07-05 2006-07-05 Purification of montelukast

Publications (1)

Publication Number Publication Date
ATE497492T1 true ATE497492T1 (de) 2011-02-15

Family

ID=37076280

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06786369T ATE497492T1 (de) 2005-07-05 2006-07-05 Reinigung von montelukast

Country Status (11)

Country Link
US (2) US7812168B2 (de)
EP (1) EP1904448B1 (de)
JP (1) JP2008510840A (de)
KR (2) KR100899585B1 (de)
CN (1) CN101213177A (de)
AT (1) ATE497492T1 (de)
CA (1) CA2608369A1 (de)
DE (1) DE602006019964D1 (de)
ES (1) ES2358923T3 (de)
IL (1) IL185731A0 (de)
WO (1) WO2007005965A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1646612B1 (de) 2004-04-21 2009-07-01 Teva Pharmaceutical Industries Ltd Verfahren zur herstellung von montelukast-natrium
EP1948612A2 (de) * 2005-11-16 2008-07-30 Teva Pharmaceutical Industries Ltd Verfahren zum trocknen von montelukast-natrium durch azeotrope entfernung des lösungsmittels
US8178680B2 (en) * 2005-12-13 2012-05-15 Msn Laboratories Limited Process for the preparation of Montelukast and its pharmaceutically acceptable salts
EP1886998A1 (de) 2006-08-09 2008-02-13 Esteve Quimica, S.A. Verfahren zur Reinigung von Montelukast und dessen Aminesalzen
US8115004B2 (en) * 2006-11-20 2012-02-14 Msn Laboratories Limited Process for pure montelukast sodium through pure intermediates as well as amine salts
US20080188664A1 (en) * 2007-01-15 2008-08-07 Chemagis Ltd. Process for preparing montelukast sodium containing controlled levels of impurities
PL205444B1 (pl) * 2007-05-02 2010-04-30 Zak & Lstrok Ady Farmaceutyczn Sposób wytwarzania soli sodowej kwasu 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-etenylo)fenylo)-3-(2-(1-hydroksy-1- metyloetylo)fenylo)propylo)sulfanylo)metylo)-cyklopropanooctowego
CZ302518B6 (cs) * 2007-07-09 2011-06-29 Zentiva, A. S. Zpusob izolace a cištení montelukastu
WO2009027990A1 (en) * 2007-08-29 2009-03-05 Morepen Laboratories Limited Salts of montelukast and process therefor
WO2009117381A2 (en) * 2008-03-17 2009-09-24 Dr. Reddy's Laboratories Ltd. Preparation of montelukast and its salts
WO2009144742A2 (en) * 2008-05-26 2009-12-03 Aptuit Laurus Pvt Limited An improved process for preparing montelukast and salts thereof
EP2287154A1 (de) 2009-07-14 2011-02-23 KRKA, D.D., Novo Mesto Effiziente Synthese zur Herstellung von Montelukast
US8546573B2 (en) * 2009-11-18 2013-10-01 Cadila Healthcare Limited Process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxy-camptothecin hydrochloride trihydrate
WO2011121091A1 (en) 2010-03-31 2011-10-06 Krka, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
KR100990046B1 (ko) * 2010-07-30 2010-10-26 동국제약 주식회사 신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법
JP2015010049A (ja) * 2013-06-27 2015-01-19 株式会社トクヤマ モンテルカストアルキルエステルを製造する方法
CN103570618A (zh) * 2013-09-30 2014-02-12 浙江车头制药股份有限公司 一种孟鲁司特钠盐的制备方法
CN103570619B (zh) * 2013-11-08 2015-12-09 南京靖龙药物研发有限公司 一种孟鲁司特钠衍生物的制备方法
CN103772275B (zh) * 2013-12-30 2015-10-28 浙江车头制药股份有限公司 孟鲁司特二正丙胺盐晶型及制备方法和应用
EP3134076A4 (de) * 2014-04-25 2017-12-20 R.P. Scherer Technologies, LLC Stabile montelukast-lösung
CN104119270A (zh) * 2014-08-12 2014-10-29 牡丹江恒远药业有限公司 一种孟鲁司特钠的制备方法
CN105924392B (zh) * 2016-02-29 2018-03-02 山东新时代药业有限公司 一种孟鲁司特钠制备方法
CN105585524B (zh) * 2016-02-29 2018-03-02 山东新时代药业有限公司 一种由孟鲁司特酸制备孟鲁司特钠的方法
CN107049940A (zh) * 2017-03-10 2017-08-18 重庆西南医院 一种促进孟鲁司特钠经直肠吸收的促进剂及其使用方法
CN108125908A (zh) * 2017-12-14 2018-06-08 重庆西南医院 一种孟鲁司特钠鼻用溶液及其制备方法
CN110045049B (zh) * 2018-01-17 2021-07-09 天津药物研究院有限公司 一种同时测定孟鲁司特钠及其制剂多种有关物质的方法
US10966943B2 (en) 2018-09-06 2021-04-06 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851409A (en) 1986-02-14 1989-07-25 Merck Frosst Canada Inc. 2-substituted quinoline dioic acids and pharmaceutical compositions
DE3611108C1 (de) 1986-04-03 1987-07-30 Balcke Duerr Ag Verfahren und Vorrichtung zur druckdichten Befestigung von geraden Rohren zwischen zwei Rohrscheiben
US5428033A (en) 1990-10-12 1995-06-27 Merck Frosst Canada, Inc. Saturated hydroxyalkylquinoline acids as leukotriene antagonists
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5266568A (en) 1990-10-12 1993-11-30 Merck Frosst Canada, Inc. Hydroxyalkylquinoline ether acids as leukotriene antagonists
CA2053209C (en) 1990-10-12 1998-12-08 Michel L. Belley Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5856322A (en) 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
IE920499A1 (en) 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists
US5506227A (en) 1992-04-13 1996-04-09 Merck Frosst Canada, Inc. Pyridine-substituted benzyl alcohols as leukotriene antagonists
TW448160B (en) 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
FI946209A0 (fi) 1994-12-30 1994-12-30 Nokia Telecommunications Oy Foerfarande foer jaemfoerande av attributvaerden hos kontrollerbara objektuttryck i ett naetelement
US5523477A (en) 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5869673A (en) 1997-02-28 1999-02-09 Merck & Co., Inc. Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde
US5952347A (en) 1997-03-13 1999-09-14 Merck & Co., Inc. Quinoline leukotriene antagonists
GB9812413D0 (en) 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
FI104718B (fi) * 1998-06-18 2000-03-31 Orion Yhtymae Oyj [[4-(2-atsido-3-metyyli-5-oksotetrahydrofuran-2-yyli)fenyyli]hydratsono]propaanidinitriili käytettäväksi referenssiaineena levosimendaanierien analyysissä
CN1420113A (zh) 2001-11-16 2003-05-28 北京上地新世纪生物医药研究所 孟鲁司特钠的制备方法及其制备中间体
CN1171873C (zh) 2001-12-26 2004-10-20 北京上地新世纪生物医药研究所 一种孟鲁司特钠的制备方法及其制备中间体
AU2003209043A1 (en) 2002-02-07 2003-09-02 Dr. Reddy's Laboratories Ltd. Novel anhydrous amorphous forms of montelukast sodium salt
US20050107612A1 (en) 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
JP2006523699A (ja) 2003-04-15 2006-10-19 メルク　エンド　カムパニー　インコーポレーテッド モンテルカストナトリウムの多形形態
CA2528228C (en) * 2003-06-06 2011-09-20 Morepen Laboratories Limited A method for the preparation of montelukast acid and sodium salt thereof in amorphous form
AU2004283832B2 (en) * 2003-10-10 2011-04-07 Synthon B.V. Solid-state montelukast
US7482460B2 (en) * 2003-12-10 2009-01-27 Hypnion, Inc. Doxepin analogs and methods of use thereof
EP1709001A2 (de) 2004-01-28 2006-10-11 Pliva Istrazivanje i Razvoj d.o.o. Feste formen von montelukastsäure
WO2005075427A2 (en) 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast sodium polymorphs
CA2554572A1 (en) 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
BRPI0506610A (pt) 2004-02-03 2007-05-02 Chemagis Ltd montelucaste sódico amorfo, processo de preparação de montelucaste sódico amorfo, composição farmacêutica, método de tratamento utilizando a administração de montelucaste sódico amorfo, co-precipitado amorfo de montelucaste sódico e processo de preparação de co-precipitado amorfo de montelucaste sódico
US7189853B2 (en) 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
EP1646612B1 (de) 2004-04-21 2009-07-01 Teva Pharmaceutical Industries Ltd Verfahren zur herstellung von montelukast-natrium
US7829716B2 (en) 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US7589128B2 (en) 2004-06-01 2009-09-15 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Process for preparation of amorphous form of a drug
ATE500225T1 (de) * 2004-07-19 2011-03-15 Matrix Lab Ltd Verfahren zur herstellung von montelukast und salzen davon
WO2006021974A1 (en) 2004-08-23 2006-03-02 Morepen Laboratories Limited A process for synthesizing diol (viii)-an intermediate of montelukast sodium
PL205637B1 (pl) 2004-10-22 2010-05-31 Inst Farmaceutyczny Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli
US20080146809A1 (en) 2004-11-19 2008-06-19 Matrix Laboratories Ltd Process for the Preparation of Novel Amorphous Montelukast Sodium
WO2006058545A1 (en) 2004-11-30 2006-06-08 Medichem, S.A. New process for the preparation of a leukotriene antagonist
WO2006064269A2 (en) 2004-12-17 2006-06-22 Cipla Limited Salts of leukotriene antagonist montelukast
ITMI20050247A1 (it) 2005-02-18 2006-08-19 Chemi Spa Processo per la preparazione di montelukast
WO2007004237A2 (en) 2005-07-05 2007-01-11 Matrix Laboratories Ltd A process for the preparation of montelukast
WO2007012075A2 (en) 2005-07-20 2007-01-25 Dr. Reddy's Laboratories Ltd. Preparation of montelukast
EP1783117A1 (de) 2005-11-04 2007-05-09 Esteve Quimica, S.A. Verfahren zur Herstellung eines Leukotrienantagonisten und dessen Zwischenprodukte
EP1948612A2 (de) 2005-11-16 2008-07-30 Teva Pharmaceutical Industries Ltd Verfahren zum trocknen von montelukast-natrium durch azeotrope entfernung des lösungsmittels
AR057908A1 (es) 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast e intermediarios del mismo
US8178680B2 (en) 2005-12-13 2012-05-15 Msn Laboratories Limited Process for the preparation of Montelukast and its pharmaceutically acceptable salts
EP1968942A4 (de) 2005-12-23 2010-06-02 Glade Organics Private Ltd Verbessertes verfahren zur herstellung von montelukast-natrium
WO2007096875A2 (en) 2006-02-21 2007-08-30 Chemagis Ltd. Novel polymorphs of montelukast ammonium salts and processes for preparation therefor
WO2007096889A2 (en) 2006-02-27 2007-08-30 Chemagis Ltd. Process for preparing montelukast and salts thereof
EP2004609A2 (de) 2006-03-06 2008-12-24 Farmaprojects, S.A. Verfahren zur herstellung eines leukotrienantagonisten
CN101432267A (zh) 2006-03-17 2009-05-13 斯索恩有限公司 孟鲁司特金刚烷胺盐
EP2004608B1 (de) 2006-04-12 2011-09-14 Glade Organics Private Limited Verbessertes verfahren zur herstellung von montelukast-natrium
US20060223999A1 (en) 2006-05-10 2006-10-05 Chemagis Ltd. Process for preparing montelukast and precursors thereof
GB0614485D0 (en) 2006-07-21 2006-09-27 Pliva Istrazivanje I Razvoj D Process
US20110092708A1 (en) 2006-08-04 2011-04-21 Seeta Ramanjaneyulu Gorantla Process for the preparation of montelukast and its salts thereof
EP1886997A1 (de) 2006-08-09 2008-02-13 Esteve Quimica, S.A. Verfahren zur Aufreinigung von Montelukast
EP1886998A1 (de) 2006-08-09 2008-02-13 Esteve Quimica, S.A. Verfahren zur Reinigung von Montelukast und dessen Aminesalzen
WO2008023044A1 (en) 2006-08-23 2008-02-28 Sandoz Ag Process for the preparation of montelukast free acid and its amine salts
NZ575552A (en) 2006-09-15 2012-02-24 Cipla Ltd Process for the preparation of montelukast, and intermediates therefor
WO2008035379A2 (en) 2006-09-19 2008-03-27 Aptuit Laurus Private Limited Process for and intermediates of leukotriene antagonists
GB0618703D0 (en) 2006-09-22 2006-11-01 Almac Sciences Ltd Synthesis of leikotriene compounds
US7700776B2 (en) 2006-10-24 2010-04-20 Formosa Laboratories, Inc. Compounds and preparation for montelukast sodium
SI22382A (sl) 2006-10-26 2008-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek za pripravo montelukasta
EP2094665A4 (de) 2006-11-06 2010-11-24 Reddys Lab Ltd Dr Herstellung von montelukast und seinen salzen
US8115004B2 (en) 2006-11-20 2012-02-14 Msn Laboratories Limited Process for pure montelukast sodium through pure intermediates as well as amine salts
KR100774088B1 (ko) 2006-12-14 2007-11-06 한미약품 주식회사 몬테루카스트의 제조방법 및 이에 사용되는 중간체
US7271268B1 (en) 2006-12-22 2007-09-18 Formosa Laboratories Inc. Process for preparation of [1-(mercaptomethyl)cyclopropyl]acetic acid and related derivatives
CZ302238B6 (cs) 2007-01-09 2011-01-05 Zentiva, A. S. Zpusob prípravy montelukastu
US20080188664A1 (en) 2007-01-15 2008-08-07 Chemagis Ltd. Process for preparing montelukast sodium containing controlled levels of impurities
EP1958936A1 (de) 2007-02-14 2008-08-20 Inke, S.A. Verfahren zur Gewinnung von Montelukast
WO2008126075A1 (en) 2007-04-12 2008-10-23 Chemagis Ltd. Process for preparing montelukast and salts thereof using optically impure 2-(2-(3(s)-(3-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-hydroxypropyl)phenyl-2-propanol
PL205444B1 (pl) 2007-05-02 2010-04-30 Zak & Lstrok Ady Farmaceutyczn Sposób wytwarzania soli sodowej kwasu 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-etenylo)fenylo)-3-(2-(1-hydroksy-1- metyloetylo)fenylo)propylo)sulfanylo)metylo)-cyklopropanooctowego
JP6546550B2 (ja) 2016-03-09 2019-07-17 日本特殊陶業株式会社 真空吸着部材および真空吸着方法

Also Published As

Publication number Publication date
US20100076195A1 (en) 2010-03-25
CN101213177A (zh) 2008-07-02
IL185731A0 (en) 2008-01-06
EP1904448A1 (de) 2008-04-02
JP2008510840A (ja) 2008-04-10
KR20090015186A (ko) 2009-02-11
ES2358923T3 (es) 2011-05-16
CA2608369A1 (en) 2007-01-11
EP1904448B1 (de) 2011-02-02
WO2007005965A1 (en) 2007-01-11
US20070078158A1 (en) 2007-04-05
US7812168B2 (en) 2010-10-12
KR20070088504A (ko) 2007-08-29
KR100899585B1 (ko) 2009-05-27
DE602006019964D1 (de) 2011-03-17

Similar Documents

Publication Publication Date Title
DE602006019964D1 (de) Reinigung von montelukast
SE0301372D0 (sv) Novel compounds
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
MXPA05013553A (es) Pirrolodihidroisoquinolinas como inhibidores de pde10.
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
EA201070247A1 (ru) Ингибиторы протеасом
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
CL2008000069A1 (es) Metodo de preparacion de compuestos derivados de 3,4-dihidroquinolina.
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
WO2005108358A3 (en) Pyrrolidine derivatives useful as bace inhibitors
SI1633697T1 (sl) Postopek za pripravo substituiranih 3-aril-butilaminskih spojin
TW200624426A (en) BACE inhibitors
IL176142A0 (en) Processes for preparing montelukast sodium
EA200601029A1 (ru) Способ очистки фсг
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
NO20063196L (no) Nye fusjonerte pyrrolokarbazoler
TW200619206A (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
DE602004018155D1 (de) Einen grössenausschlussschritt verwendendes verbessertes bisulfit-verfahren
WO2006132739A3 (en) Novel chemical compounds
WO2006135938A3 (en) Fluorometric method for monitoring a clean-in-place system
ATE539085T1 (de) Verfahren zur isolierung von haptoglobin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties